PD-1-mediated suppression of tumor-targeted immune mechanisms involves the interaction of this ICI expressed on activated, anti-tumor CD4+ and CD8+ effector T cells with PD-L1 expressed on tumor cells. This evidence concerns the gene CD4 and neoplasm.